Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from enGene Holdings ( (ENGN) ) is now available.
enGene Holdings Inc. has achieved its target enrollment of 100 patients for the pivotal cohort of its Phase 2 LEGEND trial, which evaluates the safety and efficacy of detalimogene voraplasmid in high-risk, BCG-unresponsive NMIBC patients. This milestone marks a significant step towards providing a novel non-viral gene therapy option, with plans for a Biologic License Application submission in the second half of 2026, potentially impacting the treatment landscape for NMIBC.
The most recent analyst rating on (ENGN) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on enGene Holdings stock, see the ENGN Stock Forecast page.
Spark’s Take on ENGN Stock
According to Spark, TipRanks’ AI Analyst, ENGN is a Neutral.
enGene Holdings shows significant financial challenges, with no revenue generation and persistent losses impacting both income and cash flow statements. Technical indicators suggest bearish momentum, with the stock underperforming key moving averages. The valuation is further hampered by a negative P/E ratio and absence of dividends. These factors collectively result in a low overall stock score, highlighting the company’s urgent need to establish a revenue model and improve operational efficiency.
To see Spark’s full report on ENGN stock, click here.
More about enGene Holdings
enGene Holdings Inc. is a clinical-stage biotechnology company focused on mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs. Their lead program is detalimogene voraplasmid, a non-viral gene therapy under evaluation for Non-Muscle Invasive Bladder Cancer (NMIBC), particularly targeting high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive patients.
Average Trading Volume: 86,369
Technical Sentiment Signal: Hold
Current Market Cap: $236.1M
For a thorough assessment of ENGN stock, go to TipRanks’ Stock Analysis page.